CA2502437A1 - Procede et composition contenant du latanoprost destines au traitement de l'hypertension oculaire et d'un glaucome - Google Patents

Procede et composition contenant du latanoprost destines au traitement de l'hypertension oculaire et d'un glaucome Download PDF

Info

Publication number
CA2502437A1
CA2502437A1 CA002502437A CA2502437A CA2502437A1 CA 2502437 A1 CA2502437 A1 CA 2502437A1 CA 002502437 A CA002502437 A CA 002502437A CA 2502437 A CA2502437 A CA 2502437A CA 2502437 A1 CA2502437 A1 CA 2502437A1
Authority
CA
Canada
Prior art keywords
composition
ophthalmic composition
ophthalmic
benzalkonium chloride
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002502437A
Other languages
English (en)
Other versions
CA2502437C (fr
Inventor
Ryuji Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2502437A1 publication Critical patent/CA2502437A1/fr
Application granted granted Critical
Publication of CA2502437C publication Critical patent/CA2502437C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

L'invention concerne une composition ophthalmique permettant de traiter l'hypertension oculaire et un glaucome avec des effets secondaires réduits, tels qu'une kératoconjonctivité et un oedème maculaire. Cette composition contient du latanoprost comme substance active et est sensiblement exempte de chlorure de benzalkonium. La composition selon l'invention est particulièrement utile pour le traitement d'un patient souffrant ou susceptible de souffrir d'une kératoconjonctivité et/ou d'un oedème maculaire.
CA2502437A 2002-10-24 2003-10-22 Procede et composition contenant du latanoprost destines au traitement de l'hypertension oculaire et d'un glaucome Expired - Fee Related CA2502437C (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US42077602P 2002-10-24 2002-10-24
US60/420,776 2002-10-24
US42104402P 2002-10-25 2002-10-25
US60/421,044 2002-10-25
US10/429,677 US7074827B2 (en) 2002-10-24 2003-05-06 Method for treating ocular hypertension and glaucoma
US10/429,677 2003-05-06
PCT/JP2003/013452 WO2004037267A1 (fr) 2002-10-24 2003-10-22 Procede et composition contenant du latanoprost destines au traitement de l'hypertension oculaire et d'un glaucome

Publications (2)

Publication Number Publication Date
CA2502437A1 true CA2502437A1 (fr) 2004-05-06
CA2502437C CA2502437C (fr) 2012-07-17

Family

ID=32110845

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2502437A Expired - Fee Related CA2502437C (fr) 2002-10-24 2003-10-22 Procede et composition contenant du latanoprost destines au traitement de l'hypertension oculaire et d'un glaucome

Country Status (9)

Country Link
US (2) US7074827B2 (fr)
EP (2) EP2253322A1 (fr)
JP (2) JP2006503913A (fr)
AT (1) ATE480240T1 (fr)
AU (1) AU2003274734A1 (fr)
CA (1) CA2502437C (fr)
DE (1) DE60334134D1 (fr)
DK (1) DK1553953T3 (fr)
WO (1) WO2004037267A1 (fr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004283091A1 (en) * 2003-10-03 2005-05-06 Allergan, Inc. Compositions and methods comprising prostaglandin-related compounds and trefoil factor family peptides for the treatment of glaucoma with reduced hyperemia
ATE412400T1 (de) * 2004-11-09 2008-11-15 Novagali Pharma Sa Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
DE102005035986B4 (de) * 2005-07-28 2009-10-15 Bausch & Lomb Incorporated Steriles tropfbares mehrphasiges emulgatorfreies ophthalmisches Präparat
CN101282714B (zh) * 2005-10-10 2012-12-12 诺瓦加利制药公司 包含前列腺素的眼用乳剂
CA2681668C (fr) 2006-03-23 2014-04-01 Michael S. Singer Compositions comprenant des analogues de la prostaglandine f2-alpha et procedes pour reduire la graisse corporelle
TWI394564B (zh) * 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
EP2066300B2 (fr) * 2006-09-28 2019-01-23 Novartis Ag Compositions pharmaceutiques aqueuses à conservation spontanée
FR2912207B1 (fr) * 2007-02-01 2012-10-26 Air Liquide Procede et appareil de production de monoxyde de carbone par distillation cryogenique
WO2008096804A1 (fr) * 2007-02-07 2008-08-14 Teika Pharmaceutical Co., Ltd. Préparation de gouttes ophtalmiques comprenant du latanoprost
JP2008247828A (ja) * 2007-03-30 2008-10-16 Wakamoto Pharmaceut Co Ltd ラタノプロストを含有する水性医薬組成物。
FR2918891B1 (fr) * 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
JP2009040727A (ja) * 2007-08-09 2009-02-26 Towa Yakuhin Kk ラタノプロストを有効成分とする安定な点眼液剤
JP5327809B2 (ja) * 2007-08-29 2013-10-30 わかもと製薬株式会社 ラタノプロスト含有水性医薬組成物
MX2007011165A (es) * 2007-09-12 2009-03-11 Arturo Jimenez Bayardo Composición farmacéutica estable de timolol, dorzolamida y brimonidina.
JP5583111B2 (ja) * 2008-03-17 2014-09-03 アルコン リサーチ， リミテッド ボレート−ポリオール錯体を含有する水性薬学的組成物
TWI544927B (zh) * 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (fr) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Procédé et composition pour traiter l'hypertension oculaire et le glaucome
EP2228058A1 (fr) 2009-03-04 2010-09-15 Novagali Pharma S.A. Émulsion anionique d'huile dans l'eau contenant des prostaglandines et leurs utilisations
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US20100298335A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and Methods for Ameliorating or Reducing Presbyopia
JP2010275259A (ja) * 2009-05-29 2010-12-09 Toa Yakuhin Kk 均一、かつ安定なラタノプロスト点眼液剤組成物
TWI489997B (zh) * 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物
EP2269575A1 (fr) 2009-06-30 2011-01-05 Santen Pharmaceutical Co., Ltd Procédé pour améliorer le biodisponibilité du latanoprost
EP2389939A1 (fr) 2010-05-28 2011-11-30 Novagali Pharma S.A. Utilisation de prostaglandines F2alpha et analogues pour la cicatrisation des lésions de la cornée et du conjonctif
KR101656121B1 (ko) 2010-03-17 2016-09-08 노바리크 게엠베하 안압 증가를 치료하기 위한 약학 조성물
FR2961694B1 (fr) * 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
WO2012015996A2 (fr) * 2010-07-29 2012-02-02 Allergan, Inc. Solutions de bimatoprost sans conservateur
CA2807081C (fr) * 2010-07-29 2018-09-18 Allergan, Inc. Solutions de bimatoprost et de timolol sans conservateur
US9061034B2 (en) 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
EP2452669A1 (fr) 2010-10-29 2012-05-16 Omnivision GmbH Composition ophtalmique
EP2462921A1 (fr) 2010-11-11 2012-06-13 Novaliq GmbH Compositions pharmaceutiques liquides pour le traitement d'une maladie de la chambre postérieure de l'oeil
EP3378480A1 (fr) 2011-01-19 2018-09-26 Topokine Therapeutics, Inc. Procédés et compositions de traitement du syndrome métabolique
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
CN107970506B (zh) * 2012-04-10 2020-06-16 艾诺维亚股份有限公司 具有可控制的微滴电荷的定向微滴流在制备药物中的用途
EA201491906A1 (ru) 2012-04-20 2015-03-31 Айновиа, Инк. Распылительное эжекторное устройство и способы его использования
KR102168906B1 (ko) 2012-05-14 2020-10-22 아이노비아 인코포레이티드 층류 액적 생성기 디바이스 및 이용 방법들
EP2849949A4 (fr) 2012-05-15 2017-07-26 Eyenovia, Inc. Dispositifs éjecteurs, procédés, pilotes, et circuits correspondants
JP6039152B2 (ja) 2012-09-12 2016-12-07 ノバリック ゲーエムベーハー 半フッ素化アルカン組成物
CA2869676C (fr) 2012-11-21 2015-06-23 Topokine Therapeutics, Inc. Utilisations et compositions comprenant de la thiazolidinedione et de l'acide oleique pour augmenter localement la graisse sous-cutanee
WO2014159679A1 (fr) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Procédés pour utiliser la lubiprostone pour absorber un fluide depuis l'espace sous-rétinien
NO2753788T3 (fr) 2013-05-10 2018-06-16
US9820993B2 (en) 2013-05-15 2017-11-21 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
TW201542196A (zh) * 2013-08-26 2015-11-16 Rohto Pharma 眼科用製劑
GR1008483B (el) * 2013-12-23 2015-05-12 Rafarm Α.Ε.Β.Ε., Οφθαλμικη φαρμακευτικη συνθεση και μεθοδος για την παρασκευη αυτης
US10188661B2 (en) 2014-06-27 2019-01-29 Topokine Therapeutics, Inc. Topical dosage regimen
US10326270B2 (en) 2014-08-05 2019-06-18 Sony Corporation DC power transmission device, DC power reception device, and DC power transmission system
DE202016008738U1 (de) 2015-09-30 2019-04-09 Novaliq Gmbh Semifluorierte Verbindungen und ihre Zusammensetzungen
CN108349855B (zh) 2015-09-30 2021-07-20 诺瓦利克有限责任公司 用于眼部给药的半氟化化合物
GR1009040B (el) * 2016-04-19 2017-05-19 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου
ES2763121T3 (es) 2016-06-23 2020-05-27 Novaliq Gmbh Método de administración tópica
CN116172987A (zh) 2016-09-22 2023-05-30 诺瓦利克有限责任公司 用于治疗睑缘炎的药物组合物
US10813976B2 (en) 2016-09-23 2020-10-27 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
CN111372566A (zh) 2017-09-27 2020-07-03 诺瓦利克有限责任公司 用于治疗眼部疾病的包含拉坦前列素的眼科用组合物
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
SG11202007858VA (en) 2018-03-02 2020-09-29 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
SG11202102820VA (en) 2018-10-12 2021-04-29 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
PL3886799T3 (pl) 2019-08-07 2024-03-18 Aneira Pharma, Inc. Kompozycje do leczenia utraty włosów
JP2022120120A (ja) * 2022-06-13 2022-08-17 東亜薬品株式会社 眼科用水性組成物及びプロスタグランジンＦ２α誘導体の含量の低下を抑制する方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990002553A1 (fr) * 1988-09-06 1990-03-22 Pharmacia Ab Derives de prostaglandine servant au traitement des glaucomes ou de l'hypertension oculaire
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
AU665287B2 (en) 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
WO1997023225A1 (fr) 1995-12-22 1997-07-03 Alcon Laboratories, Inc. Combinaisons de prostaglandines de type dp et fp destinees a abaisser la pression intraoculaire
JPH10259179A (ja) * 1996-09-19 1998-09-29 Santen Pharmaceut Co Ltd 多置換アリールオキシ基を有するプロスタグランジン類およびその用途
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US6646001B2 (en) * 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
JP4000505B2 (ja) * 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
SE0002211D0 (sv) 2000-06-13 2000-06-13 Synphora Ab Methods and compositions for prevention of myopia
US20020035148A1 (en) * 2000-07-20 2002-03-21 Ryuji Ueno Treatment of ocular hypertension
PT1321144E (pt) 2000-09-13 2011-03-10 Santen Pharmaceutical Co Ltd Colírio
JP3876355B2 (ja) * 2000-09-13 2007-01-31 参天製薬株式会社 点眼液
AR035541A1 (es) 2000-11-13 2004-06-16 Pharmacia Ab Un metodo de tratamiento para pacientes que sufren de glaucoma severo o necesitan una reduccion de la presion intraocular (pio) y el uso de una combinacion de agentes reductores de la pio
US8549114B2 (en) * 2002-06-12 2013-10-01 Bladelogic, Inc. Method and system for model-based heterogeneous server configuration management
KR20100132557A (ko) * 2002-08-23 2010-12-17 산텐 세이야꾸 가부시키가이샤 라타노프로스트를 유효 성분으로 하는 점안액의 안정화 방법
KR20050057251A (ko) 2002-09-09 2005-06-16 산텐 세이야꾸 가부시키가이샤 라타노프로스트를 유효 성분으로 하는 투명한 점안액

Also Published As

Publication number Publication date
US8673973B2 (en) 2014-03-18
US20040082660A1 (en) 2004-04-29
WO2004037267A1 (fr) 2004-05-06
CA2502437C (fr) 2012-07-17
US7074827B2 (en) 2006-07-11
DE60334134D1 (de) 2010-10-21
JP2006503913A (ja) 2006-02-02
AU2003274734A1 (en) 2004-05-13
ATE480240T1 (de) 2010-09-15
EP2253322A1 (fr) 2010-11-24
JP2012162570A (ja) 2012-08-30
EP1553953B1 (fr) 2010-09-08
DK1553953T3 (da) 2010-10-25
EP1553953A1 (fr) 2005-07-20
US20060205725A1 (en) 2006-09-14

Similar Documents

Publication Publication Date Title
CA2502437A1 (fr) Procede et composition contenant du latanoprost destines au traitement de l'hypertension oculaire et d'un glaucome
JP2006503913A5 (fr)
US10792288B2 (en) Preservative free brimonidine and timolol solutions
PL396553A1 (pl) Zastosowanie czynnika do wytwarzania leku do leczenia jaskry
AU772406B2 (en) Use of H1 antagonist and a safe steroid to treat eye conditions
KR101820184B1 (ko) 방부제가 없는 비마토프로스트 및 티몰롤 용액
JP2011093923A (ja) 点眼剤
US20150099807A1 (en) Preservative free bimatoprost solutions
JP2002316926A (ja) コンタクトレンズ用眼科用組成物及び眼刺激性の緩和方法
JP5041761B2 (ja) 眼粘膜適用製剤
JP2003073303A (ja) 眼局所用液剤の清涼化作用の持続方法
EP3369422A1 (fr) Préparation externe
MXPA04000980A (es) Tratamiento de hipertension ocular y glaucoma.
JPH06211665A (ja) ジラゼプを必須成分とする眼圧降下剤
EP1415666A4 (fr) Compositions de medicaments pour usage ophtalmologique

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20151022